Hechos relevantes
Los hechos relevantes incluídos en esta sección corresponden exactamente con aquellos enviados a la Comisión Nacional del Mercado de Valores (CNMV) y publicados en su página web.
Fecha | PDF | Hecho relevante | Contenido |
13/05/2013 |  | Complemento documento informativo - Dividendo flexible | |
07/05/2013 | | Almirall anuncia conferencia y webcast de resultados del 1er trimestre de 2013 | |
06/05/2013 | | Documento informativo sobre el dividendo flexible | |
03/05/2013 | | Almirall informa de los acuerdos aprobados en la Junta General de Accionistas celebrada hoy 3 de mayo de 2013 | |
03/05/2013 | | Almirall comunica el calendario sobre el dividendo flexible | |
02/05/2013 | | Resultados positivos del segundo estudio de Fase III de la combinación aclidinio + formoterol | |
16/04/2013 | | Resultados positivos del primer estudio de Fase III de la combinación aclidinio + formoterol | |
18/03/2013 | | Almirall anuncia resultados positivos del desarrollo de aclidinio en Japón | |
26/02/2013 | | Hecho relevante rectificativo respecto al publicado ayer (nº18274) por contener un error mecanográfico de trascripción en la numeración del Orden del Día de la Convocatoria de Junta General Ordinaria de Accionistas | |
25/02/2013 | | Junta General de Accionistas 2013 | |
25/02/2013 | | Almirall anuncia conferencia y webcast de resultados anuales 2012 | |
23/01/2013 | | Almirall anuncia hoy su calendario financiero para el 2013 | |
17/01/2013 | | Lanzamiento de Eklira® Genuair® en España y otros países europeos |
Fecha | PDF | Hecho relevante | Contenido |
11/12/2012 | | Almirall y Forest Laboratories anuncian que Tudorza™ Pressair™ ya está disponible en las farmacias de los Estados Unidos | |
28/11/2012 | | Linaclotida aprobada en Europa | |
19/11/2012 | | Almirall nombra a Karin Louise Dorrepaal como nueva consejera independiente | |
23/10/2012 | | Almirall anuncia la entrada en el capital de la biotecnológica AB-Biotics | |
22/10/2012 | | Acuerdos sociales aprobados en la Junta General Extraordinaria de Accionistas celebrada el pasado viernes 19 de octubre de 2012 | |
21/09/2012 | | Linaclotida recibe la opinión positiva del CHMP para el tratamiento del síndrome del intestino irritable con estreñimiento (SII-E) | |
27/07/2012 | | Anuncio de próxima Junta General Extraordinaria de Accionistas el 19 de octubre de 2012 en Barcelona | |
25/07/2012 | | Anuncio de dos cobros vinculados a las aprobaciones de aclidinio en Europa y en EE.UU. | |
24/07/2012 | | Aclidinio aprobado en Europa | |
24/07/2012 | | Almirall, S.A. y Forest Laboratories, Inc. han anunciado que la Food and Drug Administration (FDA) ha aprobado el bromuro de aclidinio para el tratamiento de la EPOC | |
08/06/2012 | | HR Admision a cotizacion nuevas acciones | |
30/05/2012 | | HR Cierre del periodo de negociacion | |
11/05/2012 | | Complemento documento informativo - Dividendo flexible | |
07/05/2012 | | Documento informativo - Dividendo flexible | |
04/05/2012 | | Cargos y Comités | |
04/05/2012 | | Calendario dividendo flexbile | |
04/05/2012 | | Acuerdos JGA2012 | |
29/03/2012 | | Almirall y Forest Laboratories anuncian que la FDA ha extendido el período de revisión del dossier de bromuro de aclidinio | |
26/03/2012 | | Almirall y Menarini firman una alianza comercial para aclidinio en la mayoria de paises en la UE y otros territorios europeos | |
27/03/2012 | | Corrección anuncio convocatoria | |
27/02/2012 | | Anuncio de próxima Junta General de Accionistas el 4 de Mayo de 2012 en Barcelona | |
24/02/2012 | | Almirall y Forest anuncian recomendación positiva del Comité Asesor de la FDA para el aclidinio | |
09/02/2012 | | Almirall co-promocionará el anticoagulante de Bayer Rivaroxaban |
Fecha | PDF | Hecho relevante | Contenido |
16/11/2011 | | Almirall comienza la fase III del aclidinio más formoterol para el tratamiento de la EPOC | |
24/10/2011 | | Almirall presenta resultados completos de dos ensayos clínicos pivotales de fase III de la linaclotida en la 19ª Semana Europea de Gastroenterología (UEGW) en Estocolmo | |
19/10/2011 | | Almirall anuncia un acuerdo de co-promoción con Lundbeck para escitalopram en Italia | |
04/10/2011 | | Almirall anuncia una actualización de sus previsiones financieras 2011-2012 | |
03/10/2011 | | Almirall anuncia el lanzamiento de roflumilast en España | |
29/09/2011 | | Almirall anuncia un acuerdo de licencia con Nycomed para la ebastina en China y otros mercados clave del sudeste asiático | |
29/09/2011 | | Almirall presenta a registro la linaclotida en Europa, para el tratamiento del síndrome de intestino irritable con estreñimiento (SII-E) | |
27/09/2011 | | Almirall anuncia que los pacientes con EPOC tratados con aclidinio perciben la mejoría desde la primera dosis según resultados del estudio ATTAIN de Fase III | |
26/08/2011 | | Almirall remite
comunicación recibida de los accionistas mayoritarios sobre su intención de iniciar un proceso de compra de hasta el 1,5% del capital de Almirall en los próximos 6 meses | |
27/07/2011 | | Almirall anuncia la presentación del registro del bromuro de aclidinio para el tratamiento de la EPOC en Europa | |
26/07/2011 | | Almirall anuncia cambios en la composición del Consejo de Administración y del Reglamento Interno de Conducta | |
05/07/2011 | | Almirall refuerza su negocio en Alemania con dos nuevos productos: Sativex® y Actikerall® | |
30/06/2011 | | Almirall anuncia la presentación del registro del bromuro de aclidinio para el tratamiento de la EPOC en los EEUU | |
08/06/2011 | | Almirall anuncia la aprobación de Sativex® en Dinamarca para el tratamiento de la espasticidad en la esclerosis múltiple (EM) | |
06/06/2011 | | Almirall anuncia el lanzamiento de Actikerall® en el Reino Unido para el tratamiento de la queratosis actínica, incluyendo grados I y II | |
01/06/2011 | | Almirall announces that Daniel Martínez Carretero has been appointed Chief Financial Officer (CFO) | |
26/05/2011 | | Almirall announces Sativex® has been approved in Germany for the treatment of spasticity due to Multiple Sclerosis | |
20/05/2011 | | Almirall announces the renewal of the members of the Auditing Committee and the Appointment and Commission Committee | |
09/05/2011 | | Almirall announces Actikerall® receives positive recommendation and process enters national approval phase in 7 European countries | |
09/05/2011 | | Almirall announces that is presenting additional data from ATTAIN (Phase III study) of aclidinium bromide at the annual ATS 2011 | |
06/05/2011 | | Announcement of dividend approval and other agreements reached at today's AGM | |
05/05/2011 | | Almirall announces a commercialization agreement with Nycomed for roflumilast in Spain | |
22/03/2011 | | Almirall announces that Sativex® is recommended for approval in all six European countries | |
17/03/2011 | | Almirall announces the appointment of a new CEO | |
14/03/2011 | | Almirall announces the launch of Sativex® in Spain to treat spasticity in multiple sclerosis | |
28/02/2011 | | Announcement of next AGM on May 6th 2011 in Barcelona | |
24/02/2011 | | Almirall announces a licensing agreement in Japan with aclidinium bromide | |
16/02/2011 | | Almirall announces that the reimbursement for Sativex® in Spain has been granted, for the treatment of spasticity in multiple sclerosis | |
04/01/2011 | | Almirall announces positive phase III results of aclidinium bromide |
Fecho | PDF | Hecho relevante | Contenido |
23/11/2010 | | Almirall announces that Sativex® enters Phase III clinical programme in oncological pain " | |
18/11/2010 | | Almirall announces a change in the composition of the Management | |
05/11/2010 | | Almirall announces a milestone payment to Ironwood after the positive results from the two Phase III trials of linaclotide | |
01/11/2010 | | Almirall announces positive results from the second Phase III trial of linaclotide in patients with irritable bowel syndrome with constipation | |
29/10/2010 | | Almirall reports preliminary topline results from the ACCORD COPD II Phase III study of aclidinium bromide in Chronic Obstructive Pulmonary Disease (COPD) | |
13/09/2010 | | Almirall announces positive results from a phase 3 trial with linaclotide in patients with irritable bowel syndrome with constipation | |
28/07/2010 | | Almirall announces that Sativex® receives regulatory authorisation in Spain | |
26/07/2010 | | Almirall signs a co-promotion agreement with Pfizer to commercialise Conbriza® in Spain, a new therapeutic option to treat osteoporosis | |
23/07/2010 | | Almirall announces an agreement with Meda | |
15/06/2010 | | Almirall announces an international agreement with Basilea to commercialize Toctino® (alitretinoin) for severe chronic hand eczema | |
01/06/2010 | | Almirall updates 2010 financial guidance | |
20/05/2010 | | Almirall announces that regulators in UK and Spain confirm Sativex® is approvable | |
14/05/2010 | | Announcement of dividend approval and other agreements reached at today's AGM | |
11/05/2010 | | Almirall to present data from studies of Eklira® (aclidinium bromide) in Chronic Obstructive Pulmonary Disease (COPD) and LAS100977 in asthma | |
10/05/2010 | | Information related to the Long term incentive plan for Executives | |
05/03/2010 | | Announcement of next AGM on May 14th 2010 in Barcelona | |
25/02/2010 | | Announcement of the approvals taken by the Board of Directors related to the Art. 116 of the Spanish Exchange Law report, the report on the Remuneration Policy adn the Audit Commitee Report 2009 | |
08/02/2010 | | Almirall announced silodosin has been approved by the European Commission | |
26/01/2010 | | Almirall announces that it has strengthened its focus to the twice-daily dosing of Eklira® in Chronic Obstructive Pulmonary Disease (COPD) | |
07/01/2010 | | Announcement of positive results from the ACCORD COPD I Phase III study of aclidinium bromide in Chronic Obstructive Pulmonary Disease (COPD) |
Fecha | PDF | Hecho relevante | Contenido |
17/12/2009 | | Announcement of an agreement between Almirall and Forest Laboratories to expand respiratory collaboration | |
10/11/2009 | | Announcement of a US$ 15 M equity investment in Ironwood Pharmaceuticals for linaclotide | |
20/10/2009 | | Announcement of Eklira update: Positive results in a comparative trial and announcement of new Phase III studies | |
09/09/2009 | | Announcement of the filing of once daily aclidinium bromide for COPD in Europe in early 2010 | |
30/07/2009 | | 1st Half 2009 Financial results presentation | |
30/07/2009 | | 1st Half 2009 Financial Results Presentation to analysts and investors | |
01/07/2009 | | Announcement of the change to our company name from Laboratorios Almirall, S.A. to Almirall, S.A. | |
22/05/2009 | | Announcement of dividend approval and other agreements reached at today's AGM. | |
04/05/2009 | | Announcement of a pan-European licensing-in agreement with Ironwood for linaclotide, a novel gastrointestinal compound | |
30/04/2009 | | Announcement of an update of the respiratory pipeline | |
03/04/2009 | | Announcement of a co-marketing agreement with Recordati for the marketing of silodosin in Spain, a new compound for benign prostatic hyperplasia | |
01/04/2009 | | Announcement of a milestone payment of £8 million (approx. € 8,6 million), after the positive results in the Sativex's phase III study, to its partner GW Pharmaceuticals plc. and for which Almirall has the marketing rights throught Europe, expect in the United Kingdom | |
12/03/2009 | | Announcement of positive preliminary phase III results of Sativex for the treatment of spasticity, for which Almirall has the marketing rights throught Europe, expect in the United Kingdom | |
06/03/2009 | | Announcement of an update on the Aclidinium Bromide Clinical Development Program | |
27/02/2009 | | Announcement of next AGM on May 22nd 2009 in Barcelona | |
27/02/2009 | | 2nd Half 2008 Financial results information | |
27/02/2009 | | 2008 Corporate Governance Annual Report | |
13/01/2009 | | Announcement of the sale of 13 products for 19.1 million euros |
